CClinicalTrials.gg
WithdrawnNCT02112240Updated Jul 15, 2016

Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients

An interventional study of Intraoperative Mobile Gamma Camera imaging and Endoscopic injection of 99mTc-sulfur colloid in Rectal Cancer, sponsored by University of Virginia. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-15.

Sponsored by University of Virginia · Not applicable, Interventional, and Diagnostic

Why this study was withdrawn
No accrual. New study opening with modified technique.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to see if investigators can develop a technique to identify sentinel lymph nodes in the rectum for rectal cancer patients with the use of a radiotracer (Tc-sulfur colloid), a dye (Spot), and imaging, both pre- and intraoperatively. Eligible patients are those with stage I-III rectal cancer undergoing standard low anterior resection or abdominoperineal resection.

Investigators hypothesize that use of a unique intraoperative lymphatic mapping technique using a mobile gamma camera will identify the sentinel lymph node in patients with rectal cancer with greater than 80% sensitivity.

Subjects will receive injections of the tracer and dye prior to surgery, have preoperative SPECT/CT imaging to be used as a guide to the rectal lymphatic system and then proceed to their scheduled surgery. During surgery, images of the rectum will be taken with a unique mobile gamma camera prior to removal and upon resection.

If surgeons are able to identify the sentinel lymph nodes surrounding the rectal tumor, the hope is to combine this technique with a less invasive surgery called transanal endoscopic microsurgery (TEM) for early stage rectal cancer patients.

02

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • sentinel lymph node
  • lymphatic mapping
  • rectal tumor
03

In context

Rectal Neoplasms

1,761 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

Browse Rectal Neoplasms studies →

Lead sponsor

University of Virginia is the lead sponsor of 653 studies on the registry; 134 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 41 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients with stage I,II, or III rectal cancer undergoing standard trans- abdominal low anterior resection or abdominoperineal resection surgery at the University of Virginia
  • Willing and able to give written informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients less than 18 years of age
  • Women who are pregnant and/or breastfeeding
  • Prisoners
  • Unable to give written informed consent
  • Participants with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Surgery with pre- and intra-op imaging

    Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

    Other: Intraoperative Mobile Gamma Camera imaging · Drug: Endoscopic injection of 99mTc-sulfur colloid · Other: Endoscopic injections of Spot · Procedure: Preoperative flexible sigmoidoscopy · Radiation: SPECT/CT

Interventions

  • OtherIntraoperative Mobile Gamma Camera imaging

    Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.

  • DrugEndoscopic injection of 99mTc-sulfur colloid

    Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.

    Also known as: Tc-sulfur colloid

  • OtherEndoscopic injections of Spot

    Dye injection for tattooing rectal tumor prior to surgical resection.

  • ProcedurePreoperative flexible sigmoidoscopy

    Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.

  • RadiationSPECT/CT

    Preoperative imaging to identify lymph nodes in rectum.

06

What researchers measure

Primary outcomes

  1. Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.

    The primary endpoint is the sensitivity of sentinel lymph node (SLN) detection by the technique which will be estimated by the number of SLNs detected by the technique divided by the number noted at surgery or on final pathology review. 90% confidences interval around the estimate will help guide interpretation of the results.

    Time frame: At the time of surgery and the time of pathological review, an expected average of 7 days.

Secondary outcomes

  1. Feasibility

    Descriptive summaries will be used to list any complications that may have occurred pre-, intra- or post-operatively. Frequency and location of the sentinel lymph node (SLN) with respect to the tumor prior to surgery will be noted. In addition the location of the SLN in relation to the tumor will be documented during pathologic examination with the pathologist and surgeon to assess the feasibility of excision with transanal endoscopic microsurgery.

    Time frame: From the time of tracer and dye injections to 30 day postoperative visit

07

Study locations

1 site
  • University of Virginia
    Charlottesville, Virginia 22908, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02112240
Lead sponsor
University of Virginia
Collaborators
American Cancer Society, Inc.
Responsible party
Traci Hedrick, MD (Assistant Professor of Surgery, University of Virginia) — Principal investigator
First posted
Apr 11, 2014
Start date
May 2013
Primary completion
Feb 2017 (estimated)
Last update
Jul 15, 2016

Study contacts

Traci L Hedrick, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion